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Plasma cells are terminally differentiated B lym­
phocytes that secrete large quantities of antibodies. 
During the initial stages of a T cell–dependent 
antibody response, plasma cells are found in the 
extrafollicular regions of secondary lymphoid 
organs (Fagraeus, 1948). These extrafollicular 
plasma cells are responsible for the initial surge 
in antibody levels after immunization or infec­
tion, but are thought to survive for only several 
days before undergoing apoptosis (Jacob et al., 
1991; Smith et al., 1994; Sze et al., 2000). A sec­
ond wave of plasma cells that express high­ 
affinity antibodies is generated from the germinal 
center reaction (Han et al., 1995; Smith et al., 
1997; Phan et al., 2006). Affinity­matured plasma 
cells egress from secondary lymphoid organs to 
seed the BM, where they can persist for many 
years (Slifka et al., 1995, 1998; Manz et al., 1997; 
Hargreaves et al., 2001; Pabst et al., 2005; 
Kabashima et al., 2006). These long­lived plasma 
cells are solely responsible for maintaining an­
tigen­specific serum antibodies long after clear­
ance of infection or vaccination (Manz et al., 
1998; Slifka et al., 1998; Cambridge et al., 
2003; Ahuja et al., 2008; DiLillo et al., 2008).
The ontogeny of long­lived plasma cells indi­
cates that signals received within the germinal 
center reaction confer longevity. Potential mecha­
nisms for determining longevity include the in­
duced expression of chemokine receptors, such as 
CXCR4 and S1PR1, which allow plasma cells to 
egress to the BM and access survival cytokines 
(Benner et al., 1981; Hargreaves et al., 2001; 
Hauser et al., 2002; Kabashima et al., 2006). One 
of the survival cytokines, APRIL, binds to its re­
ceptor BCMA and activates plasma cell–intrinsic 
antiapoptotic factors such as MCL1 (Moreaux 
et al., 2004; O’Connor et al., 2004; Belnoue et al., 
2008; Peperzak et al., 2013). XBP1 and ATG5 are 
also essential for plasma cell survival because of 
their roles in regulating ER stress (Reimold et al., 
2001; Hu et al., 2009; Pengo et al., 2013). Factors 
that establish and maintain plasma cell identity, 
such as BLIMP1, are also required for long­term 
antibody responses (Shapiro­Shelef et al., 2005).
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The duration of antibody production by long-lived plasma cells varies with the type of 
immunization, but the basis for these differences is unknown. We demonstrate that 
plasma cells formed in response to the same immunogen engage distinct survival programs 
depending on the adjuvant. After alum-adjuvanted immunization, antigen-specific bone 
marrow plasma cells deficient in the transcription factor ZBTB20 failed to accumulate 
over time, leading to a progressive loss of antibody production relative to wild-type con-
trols. Fetal liver reconstitution experiments demonstrated that the requirement for 
ZBTB20 was B cell intrinsic. No defects were observed in germinal center numbers, affinity 
maturation, or plasma cell formation or proliferation in ZBTB20-deficient chimeras. How-
ever, ZBTB20-deficient plasma cells expressed reduced levels of MCL1 relative to wild-
type controls, and transgenic expression of BCL2 increased serum antibody titers. These 
data indicate a role for ZBTB20 in promoting survival in plasma cells. Strikingly, adjuvants 
that activate TLR2 and TLR4 restored long-term antibody production in ZBTB20-deficient 
chimeras through the induction of compensatory survival programs in plasma cells. Thus, 
distinct lifespans are imprinted in plasma cells as they are formed, depending on the 
primary activation conditions. The durability of vaccines may accordingly be improved 
through the selection of appropriate adjuvants.
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reporter and measured through cleavage of the substrate fluor­
escein di–­galactopyranoside (Nolan et al., 1988). Thus, we first 
assessed the expression of ZBTB20 in heterozygous B cell pro­
genitors, naive follicular B cells, polyclonal splenic isotype­
switched memory B cells, splenic and BM plasma cells, and 
germinal center B cells from unimmunized mice to confirm 
the microarray results (Fig. S1). Flow cytometry analysis of 
Zbtb20+/trap cells showed that ZBTB20 expression was substan­
tially elevated in all activated and memory B cell populations 
relative to B cell progenitors and the naive B cell compartment 
(Fig. 1 A). The frequency of CD138hi BM plasma cells was low, 
consistent with previous studies (Manz et al., 1997; Slifka et al., 
1998). To confirm the accuracy of our gating strategy and to 
exclude the possibility of nonplasma cell contamination within 
this population, B220 CD138hi cells were double­sorted into 
­Ig– and ­Ig–coated ELISPOT wells, and IgM­ and 
IgG­containing spots were quantified. Approximately 50% of 
sorted cells gave rise to detectable spots (not depicted); this is al­
most certainly an underestimate of the true plasma cell frequency, 
as viability and postsort purity were unlikely to have been 
100%. Using gene­trap–specific Southern blotting, we con­
firmed the presence of a single insertion only within the Zbtb20 
locus (Fig. 1 B).
Consistent with previous studies using independent 
ZBTB20­deficient mouse strains, homozygous Zbtb20trap/trap 
mice did not survive to adulthood (Rosenthal et al., 2012; 
Sutherland et al., 2009). We thus performed all subsequent 
experiments using fetal liver reconstitutions of 800 cGy–
irradiated adult wild­type mice. Peripheral blood B cells derived 
from homozygous Zbtb20trap/trap fetal liver donors expressed 
approximately sixfold lower levels of ZBTB20 transcripts 
than did B cells from Zbtb20+/+ chimeras, confirming the ef­
ficacy of the gene trap mutation (Fig. 1 C). We also assessed 
hematopoietic development through competitive reconstitu­
tion assays in which CD45.2 Zbtb20trap/trap and Zbtb20+/+ fetal 
livers were cotransplanted with wild­type CD45.1 BM. No 
significant differences were observed between Zbtb20trap/trap 
and Zbtb20+/+ chimeras in their contribution to progenitors 
or mature immune cells (Fig. S2 and not depicted). Thus, 
ZBTB20 is not required for hematopoietic development.
ZBTB20 regulates long-term antibody production  
through a B cell–intrinsic mechanism
Given that ZBTB20 is dramatically induced in activated B cells, 
we next examined its role in antibody responses. For this pur­
pose, we immunized fetal liver chimeras with alum­adjuvanted 
4­hydroxy­3­nitrophenyl­acetyl (NP) conjugated to chicken 
gamma globulin (CGG), a T­dependent hapten protein con­
jugate antigen. Although NP­specific serum antibody titers 
in Zbtb20trap/trap chimeras were similar to controls at 2 wk after 
immunization, they were significantly reduced (approximately 
sixfold) relative to antibody titers in Zbtb20+/+ chimeras at 11 wk 
after immunization (Fig. 2 A). In contrast, the numbers of NP­
specific memory B cells in Zbtb20trap/trap chimeras were similar 
to controls (Fig. 2 B).
Clearly, however, additional pathways that fine­tune the 
survival of plasma cells remain to be discovered. The duration 
of antibody production and plasma cell lifespan varies widely 
with the specific vaccine or infection, yet the basis for these 
differences remains unknown (Amanna et al., 2007; Amanna 
and Slifka, 2010). Multiple recent clinical studies have shown 
that protection against malaria and Pertussis wanes rapidly 
after vaccination, leading to high rates of infection and mor­
tality in previously immunized children (Misegades et al., 2012; 
Olotu et al., 2013). Thus, an understanding of the particular 
features of vaccines and host responses that confer durable 
antibody production is of utmost importance.
In previous work, we found that ZBTB20, a member of 
the Broad complex, tramtrack, bric­a­brac­poxvirus, and 
zinc finger (BTB­POZ) family of transcriptional repressors, 
was highly expressed in plasma, germinal center, and memory 
B cells (Bhattacharya et al., 2007). Members of this family of 
transcription factors contain an N­terminal BTB­POZ do­
main that mediates homodimerization and recruitment of 
nuclear co­repressors, as well as a variable number of zinc fin­
ger domains at the C terminus, which mediate DNA binding 
(Melnick et al., 2002). Prior studies have shown that ZBTB20 
regulates pancreatic  cell function, neuronal development in 
the hippocampus, and transcription of ­fetoprotein (Xie et al., 
2008, 2010; Sutherland et al., 2009; Nielsen et al., 2010; Zhang 
et al., 2012). However, the physiological importance of ele­
vated ZBTB20 expression in activated B cells remained un­
known. Here, we demonstrate that ZBTB20 is required for 
long­term antibody production and plasma cell persistence 
specifically after alum­adjuvanted immunization. In contrast, 
maintenance of antibody production after immunization with 
TLR ligand–containing adjuvants is ZBTB20 independent. 
We conclude that long­lived plasma cells generated in response 
to the same antigen can access distinct survival programs, 
depending on the initial activation conditions experienced by 
B cells in germinal centers.
RESULTS
ZBTB20 is highly expressed in activated B cells  
but is not required for B cell development
Our previous microarray experiments demonstrated elevated 
expression of ZBTB20, a member of the BTB­POZ family of 
transcriptional repressors, after B cell activation (Bhattacharya 
et al., 2007). To study the functional role of ZBTB20 in B cells, 
we obtained a gene­trapped mouse embryonic stem cell line 
carrying an insertion within the Zbtb20 locus. The insertion 
consists of a splice acceptor, a ­galactosidase–neomycin resis­
tance fusion cassette, and a polyadenylation signal. As this pro­
moterless gene trap is integrated in the intronic region between 
exons 3 and 4 of Zbtb20 and upstream of the two known trans­
lation start sites (Mitchelmore et al., 2002), the insertion is pre­
dicted to both report and attenuate ZBTB20 expression.
We first generated heterozygous Zbtb20+/trap mice using this 
gene­trapped embryonic stem cell line. The ­galactosidase ac­
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compared with control IgG1B titers from Zbtb20+/+ chimeras 
(Fig. 3 B). Analysis of control NP­specific serum IgG1A titers re­
vealed no differences between Zbtb20+/+ and Zbtb20trap/trap mixed 
chimeras (Fig. 3 C). These data demonstrate a B cell–intrinsic 
requirement for ZBTB20 in long­term antibody responses.
As the t1/2 of IgG1 serum antibodies is 1 wk (Vieira and 
Rajewsky, 1988), antibody titers in ZBTB20­deficient chime­
ras declined at nearly the maximum possible rate 3 wk after 
immunization (Fig. 3 B). These data suggest an absence of new 
antibody production at later phases of the response, potentially 
as the result of reduced numbers of plasma cells. To directly 
quantify the number of antigen­specific BM plasma cells, we 
performed ELISPOT analysis at 2, 6, 13, and 18 wk after 
immunization. NP­specific Zbtb20trap/trap antibody­secreting cell 
(ASC) numbers were similar to controls at 2 wk after immuni­
zation (Fig. 3 D). However, by 6 and 13 wk after immunization, 
To determine whether the requirement for ZBTB20 in 
long­term NP­specific antibody production is B cell intrinsic, 
we performed mixed chimera experiments. Mice were recon­
stituted with equal numbers of IgHA wild­type fetal liver cells 
and either IgHB Zbtb20trap/trap or littermate control Zbtb20+/+ 
fetal liver cells. Allotype­specific secondary antibodies were 
then used to distinguish donor B cells and antibodies. Donor 
CD45.2 IgHA and IgHB fetal liver cells contributed equally to 
the B cell compartment, whereas residual CD45.1 recipient 
B cells were undetectable (Fig. 3 A). Mixed chimeras were im­
munized with NP­CGG as above, and analysis of NP­specific 
serum IgG1B responses demonstrated that antibody titers were 
normal at 2 wk after immunization (Fig. 3 B). However, similar 
to the data shown in Fig. 2 A, Zbtb20trap/trap­derived IgG1B anti­
body titers were progressively lost over time, reaching levels 
that were 16­fold lower at 13 wk after immunization when 
Figure 1. ZBTB20 is highly expressed by activated B cells. (A) Flow cytometry analysis of ZBTB20 expression through -galactosidase ex-
pression in Zbtb20+/trap B cell progenitors by the Hardy classification (Fr. A–F), naive B cells, splenic plasma cells, germinal center B cells, isotype-
switched memory B cells, and B220+ and B220 BM plasma cells. Gating strategies are shown in Fig. S1. Cells from heterozygous Zbtb20+/trap (solid 
lines) and control Zbtb20+/+ (dashed lines) mice were both stained with the -galactosidase substrate fluorescein di--galactopyranoside. Values 
in the top left corner of plots represent fold changes of the mean fluorescence intensities between Zbtb20+/trap and Zbtb20+/+ cells. Data are repre-
sentative of four independent experiments with one mouse per group per experiment. (B) Map of Zbtb20 locus (left) and Southern blot analysis 
(right) demonstrating the correct location and copy number of the gene trap insertion. Black numbered rectangles denote exons 2–4 of Zbtb20. 
The small solid rectangle indicates the location of the Neo-specific probe. ATG, translation start site; -gal, -galactosidase; H3, HindIII; Neo, 
neomycin phosphotransferase; pA, polyadenylation site; SA, splice acceptor. (C) qRT-PCR analysis of ZBTB20 transcript levels in peripheral blood  
B cells from Zbtb20+/+ (n = 9) and Zbtb20trap/trap (n = 8) fetal liver chimeras. Transcript levels were measured in technical triplicates, and Zbtb20 
expression was normalized to the mean Actb expression of each sample. Mean values ± SD are shown in arbitrary units (AU) relative to wild-type 
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et al., 2007; Marrack et al., 2009). Thus, we tested whether 
such pathogen­derived adjuvants engage distinct ZBTB20­
independent pathways to maintain antibody production. Fetal 
liver chimeras were immunized with the same dose of NP­CGG 
as above but adjuvanted with monophosphoryl lipid A, a TLR4 
ligand (Martin et al., 2003), and trehalose dicorynomycolate, a 
TLR2 ligand derived from Mycobacterium tuberculosis (Bowdish 
et al., 2009). This formulation is very similar to Ribi adjuvant, 
in which the bulk of long­term antibody production is TLR 
dependent (Gavin et al., 2006). We examined IgG1, IgG2b, and 
IgG2c NP­specific titers, as B cells of different isotypes can use 
distinct survival programs (Dogan et al., 2009; Pape et al., 2011; 
Wang et al., 2012). For every isotype, Zbtb20trap/trap­derived 
serum NP­specific antibody titers were similar to controls at all 
time points examined (Fig. 4 A). Moreover, antigen­specific 
BM plasma cells persisted for at least 20 wk after immunization 
in both control and Zbtb20trap/trap chimeras (Fig. 4 B). To test the 
generality of these findings, we immunized mice with a vaccine 
against West Nile virus (WNV), which activates TLR3 signal­
ing (Wang et al., 2004; Daffis et al., 2008; Xia et al., 2013). 
WNV­specific antibody titers at 21 wk and plasma cell num­
bers at 26 wk after vaccination were similar between Zbtb20+/+ 
and Zbtb20trap/trap chimeras (Fig. 4, C and D). These results 
suggest that TLR­based adjuvants use a ZBTB20­independent 
pathway for long­term antibody production, although we can­
not fully exclude the possibility that other components of the 
formulations may also have adjuvanting effects.
ZBTB20 is dispensable for germinal center  
function and plasma cell generation
Mutations or conditions that compromise durable antibody 
production often are linked to defects in the germinal cen­
ter reaction and subsequent formation of long­lived plasma 
cells. Of note, TLR ligand adjuvants can induce particularly 
ZBTB20­deficient NP­specific BM plasma cell numbers had 
failed to expand. As a result, Zbtb20+/+ NP­specific plasma 
cells outnumbered their Zbtb20trap/trap counterparts by 10­fold 
(Fig. 3 D). By 18 wk after immunization, most ZBTB20­
deficient chimeras lacked detectable numbers of NP­specific 
BM plasma cells (Fig. 3 D). Similarly, no defects in splenic NP­
specific plasma cell numbers were observed at 1 wk after immu­
nization in ZBTB20­deficient chimeras, which are mostly 
comprised of short­lived plasma cells (Fig. 3 E). However, sig­
nificant deficiencies in splenic plasma cells were observed in 
Zbtb20trap/trap chimeras at 4 and 6 wk after immunization relative 
to wild­type chimeras (Fig. 3 E). These data indicate a B cell–
intrinsic requirement for ZBTB20 to accumulate and maintain 
long­lived plasma cells for enduring antibody responses.
To determine whether ZBTB20 is required for long­term 
antibody responses to protein antigens, we quantified CGG­
specific titers over time. We again observed large defects in 
serum antibody production at late time points in ZBTB20­
deficient chimeras (Fig. 3 F). These defects manifested as a failure 
to increase CGG­specific antibodies over time, perhaps because 
monomeric CGG as an ELISA antigen only allows for the detec­
tion of high­affinity antibodies, which peak late in the response. 
Regardless, these data are consistent with the requirement for 
ZBTB20 to accumulate affinity­matured long­lived plasma 
cells, irrespective of the antigen.
Zbtb20 deficiency is overcome by inclusion  
of TLR ligand–containing adjuvants
Although the data above indicate that ZBTB20 is required for 
long­lived antibody responses irrespective of the immunizing 
antigen, other features of the immunogen may also affect the 
duration of immunity. Specifically, the use of pathogen­derived 
adjuvants, in place of aluminum salts, correlates with particu­
larly durable antibody responses in clinical vaccines (Amanna 
Figure 2. ZBTB20 is required for the long-term production of antigen-specific antibodies. Fetal liver chimeras were generated by transplant-
ing Zbtb20+/+ or Zbtb20trap/trap fetal liver cells between 14.5 and 17.5 d postcoitus into 8–12-wk-old lethally irradiated wild-type mice. Mice were im-
munized 8–16 wk after reconstitution. (A) ELISA measurements of serum NP-specific IgG1 titers from Zbtb20+/+ or Zbtb20trap/trap fetal liver chimeras at 
2 and 11 wk after alum-adjuvanted NP-CGG immunization (error bars depict geometric means ± 95% confidence interval). Each data point represents 
a geometric mean of technical duplicates. Data are representative of three experiments, each with two to eight mice per genotype. Statistical signifi-
cance was determined with the Mann–Whitney test. ns, not significant (P > 0.05); ****, P < 0.0001. (B) Frequencies of donor splenic lineage (CD3/
CD4/CD8/CD11c/Gr-1/Ter119) NP-specific memory B cells from Zbtb20+/+ or Zbtb20trap/trap fetal liver chimeras were determined by flow cytometry at 
12–16 wk after alum-adjuvanted NP-CGG immunization. Mean values ± SEM are shown, and examples of gating strategies are shown to the left. 
Data are representative of two experiments, each with four to nine mice per genotype. Statistical significance was determined with an unpaired Stu-
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these defects are overcome by TLR ligand adjuvants. To 
determine whether premature waning of antibody responses 
in ZBTB20­deficient chimeras is linked to germinal center 
defects, we quantified the numbers of germinal centers and 
robust germinal center reactions (Meyer­Bahlburg et al., 
2007; Hwang et al., 2009; Kasturi et al., 2011). We thus 
hypothesized that ZBTB20 deficiency causes defects in ger­
minal center reactions and plasma cell formation and that 
Figure 3. Requirement for ZBTB20 in maintenance 
of antibody responses is B cell intrinsic. Mixed fetal 
liver chimeras were generated by transplanting either 
Zbtb20+/+ or Zbtb20trap/trap IghB fetal liver cells with con-
genic IghA wild-type (B6.Cg-IghA Thy1AGpi1A) fetal liver 
cells at a 1:1 ratio into 8–12-wk-old lethally irradiated 
wild-type mice. Mice were immunized 8–16 wk after recon-
stitution. Ig allotype–specific secondary antibodies (IgMA vs. 
IgMB; IgG1A vs. IgG1B) were then used to distinguish donor 
B cells and antibodies. (A) Peripheral blood B cell IgMB cell 
chimerism in Zbtb20+/+ (n = 9) or Zbtb20trap/trap (n = 8) 
mixed fetal liver chimeras was determined by flow cy-
tometry at 7 wk after reconstitution. Mean values ± 
SEM are shown. Data are representative of three inde-
pendent experiments. (B and C) ELISA measurements of 
IgG1B NP-specific serum titers at multiple time points 
between 2 and 13 wk (B) and IgG1A control wild-type 
NP-specific serum titers at week 13 (C) from Zbtb20+/+ 
(n = 6) or Zbtb20trap/trap (n = 9) mixed chimeras after 
immunization (each point represents one mouse, and 
error bars depict geometric means ± 95% confidence 
interval). Data are representative of two independent 
experiments. Statistical significance was determined by 
the Mann–Whitney test. ns, not significant (P > 0.05); 
*, 0.01 < P < 0.05; ***, P < 0.001. (D and E) ELISPOT as-
says of NP-specific IgHB ASCs in the BM at 2, 6, 13, and 
18 wk (D) and in the spleen at 1, 4, and 6 wk (E) from 
Zbtb20+/+ or Zbtb20trap/trap mixed chimeras after alum-
adjuvanted NP-CGG immunization. Mean values ± SEM 
are shown. Each data point represents a mean of techni-
cal triplicates. Each time point has four to nine mice per 
genotype. Data are cumulative of two independent ex-
periments. Statistical significance was determined with 
an unpaired Student’s two-tailed t test. ns, not signifi-
cant (P > 0.05); *, 0.01 < P < 0.05; **, P < 0.01. (F) ELISA 
measurements of serum CGG-specific IgG1B titers at mul-
tiple time points between 2 and 13 wk from Zbtb20+/+ or 
Zbtb20trap/trap mixed chimeras after alum-adjuvanted  
NP-CGG immunization (each data point represents one 
mouse, and error bars depict geometric means ± 95% 
confidence interval). Data are representative of two ex-
periments, each with 8–10 mice per genotype. Statistical 
significance was determined by the Mann–Whitney test. 
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respectively). Moreover, no significant differences in ger­
minal center sizes were observed histologically when com­
paring ZBTB20­deficient and control chimeras (Fig. 5 C). 
Thus, ZBTB20­deficient germinal centers are grossly normal.
Like ZBTB20, the transcription factor AIOLOS is required 
for long­term antibody responses. Aiolos/ animals form and 
maintain germinal centers, and the extent of somatic hypermu­
tation is normal (Cortés and Georgopoulos, 2004). However, 
selection and survival of germinal center B cells carrying high­
affinity antigen receptors is blocked in Aiolos/ mice. Because 
only the high­affinity clones within germinal centers differen­
tiate into long­lived plasma cells, Aiolos/ mice form only 
short­lived plasma cells (Cortés and Georgopoulos, 2004; Phan 
et al., 2006). To test whether ZBTB20 deficiency causes a simi­
lar failure in affinity maturation, we analyzed canonical affinity­
enhancing W33L and/or K58R mutations in immunoglobulin 
heavy chain genes from NP­specific cells (Cumano and 
Rajewsky, 1986; Furukawa et al., 1999). The extent of somatic 
hypermutation and the frequency of cells carrying affinity­
enhancing mutations were similar between ZBTB20­deficient 
and control germinal center B cells (Fig. 5 D). We next exam­
ined whether ZBTB20 is required for the generation of affinity­
matured BM plasma cells. For this purpose, we sequenced 
immunoglobulin heavy chain genes from NP­specific BM 
plasma cells at 2 wk after alum­adjuvanted immunization. As 
shown in Fig. 5 E, no significant differences were observed be­
tween mutant and wild­type plasma cells after alum­adjuvanted 
immunization. Moreover, the relative affinities of polyclonal 
NP­specific serum antibodies at 11 wk after immunization 
were similar between ZBTB20­deficient and control chimeras 
(Fig. 5 F). We conclude that affinity maturation and the initial 
generation of affinity­matured BM plasma cells is unaffected 
by ZBTB20 deficiency. This phenotype is thus distinct from 
Aiolos/ and Cr2/ mice, in which long­term antibody de­
fects are linked to changes in affinity maturation (Chen et al., 
2000; Cortés and Georgopoulos, 2004).
TLR ligand–based immunogens can induce large T cell– 
and germinal center–independent antibody responses that 
can persist for many weeks (Bortnick et al., 2012; Bortnick 
and Allman, 2013). Thus, it is possible that ZBTB20 expres­
sion is important for regulating post–germinal center plasma 
cells but not T­independent long­lived plasma cells formed by 
TLR­based immunizations. Arguing against this possibility, 
NP­specific BM plasma cells in both control and ZBTB20­
deficient chimeras were extensively mutated and affinity ma­
tured after TLR ligand–adjuvanted immunization (Fig. 5 G). 
Moreover, extrafollicular splenic plasma cell numbers were 
similar after alum­ and TLR ligand–adjuvanted NP­CGG 
immunization (Fig. 5, H and I, respectively). These results sug­
gest that inclusion of TLR ligands in the adjuvant, rather than 
increasing the number of T­independent plasma cells, yields 
plasma cells derived from the germinal center that do not de­
pend on ZBTB20 for their accumulation or maintenance.
Many long­lived plasma cells are formed late in the germi­
nal center reaction, emerging 2 wk or more after immunization 
(Han et al., 1995). Some synthetic TLR ligand–containing 
their function after alum­ or TLR ligand–adjuvanted NP­
CGG immunization. The frequencies of germinal center 
B cells were similar between ZBTB20­deficient and control 
chimeras at 2 and 4 wk after immunization with alum adju­
vants and with TLR ligand adjuvants (Fig. 5, A and B, 
Figure 4. Immunization with TLR ligand–containing adjuvants 
bypasses the requirement for ZBTB20. (A) ELISA measurements  
of serum NP-specific IgG1, IgG2c, and IgG2b titers from Zbtb20+/+ or 
Zbtb20trap/trap fetal liver chimeras at 2, 9, and 19 wk after immuniza-
tion with TLR ligand–adjuvanted NP-CGG (error bars depict geometric 
means ± 95% confidence interval). Data are cumulative from two experi-
ments with 9–14 Zbtb20+/+ and 10–15 Zbtb20trap/trap chimeric mice per time 
point. Statistical significance was determined by the Mann–Whitney 
test. ns, not significant (P > 0.05). (B) ELISPOT analysis of NP-specific 
IgG1 BM ASCs from Zbtb20+/+ (n = 7) or Zbtb20trap/trap (n = 9) fetal liver 
chimeras at 20 wk after immunization (mean values ± SEM). Statistical 
significance was determined with an unpaired Student’s two-tailed  
t test. ns, not significant (P > 0.05). Data are cumulative from two inde-
pendent experiments. (C) ELISA measurements of serum WNV-specific 
IgG titers from Zbtb20+/+ (n = 3) or Zbtb20trap/trap (n = 5) fetal liver chi-
meras at 21 wk after vaccination (error bars depict geometric means ± 
95% confidence interval). Statistical significance was determined by the 
Mann–Whitney test. ns, not significant (P > 0.05). (D) ELISPOT assays of 
WNV-specific ASCs. WNV E protein–specific IgG-secreting cells in the 
BM from Zbtb20+/+ (n = 3) or Zbtb20trap/trap (n = 6) chimeric mice were 
quantified at 26 wk after vaccination. Mean values ± SEM are shown. 
Statistical significance was determined with an unpaired Student’s two-
tailed t test. (C and D) Data are representative of two experiments, each 
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Figure 5. ZBTB20 does not regulate germinal center reactions or plasma cell generation. (A and B) Flow cytometric quantification of 
Zbtb20+/+ and Zbtb20trap/trap germinal center B cells at 2 and 4 wk after immunization with alum (A)- or TLR ligand–adjuvanted (B) NP-CGG. Example 
flow cytometry plots and gating strategies are shown to the left in A. Mean values ± SEM are shown along with individual data points. Data are cumu-
lative from two experiments, with 4–9 (A) or 8–11 (B) mice per genotype per time point. Statistical significance was determined with an unpaired 
Student’s two-tailed t test. ns, not significant (P > 0.05). (C) Microscopic quantification of germinal center areas in splenic sections. Zbtb20+/+ and 
Zbtb20trap/trap germinal center areas were quantified from frozen splenic sections, obtained 2 wk after alum-adjuvanted NP-CGG immunization and 
subsequently stained with fluorescently labeled antibodies against GL7 and IgD. Example immunofluorescent microscopy images are shown to the left 
(bar, 1 mm). Both the germinal center cross section areas (middle) and relative sizes (right) are shown (mean values ± SD). Statistical significance was 
determined with an unpaired Student’s two-tailed t test. Data are cumulative from two independent experiments. (D and E) Sequencing analysis of 
heavy chain genes from individual NP-specific Zbtb20+/+ and Zbtb20trap/trap germinal center B cells (D) and BM plasma cells (E) isolated at 2 wk after 
NP-CGG immunization adjuvanted with alum. Sequences were examined for total (top; error bars depict mean values ± SD) and canonical affinity-
enhancing (bottom) somatic mutations. Statistical significance was determined with a Mann–Whitney test. Each data point represents sequence from 
an individual cell. Data are cumulative from two independent experiments, each with two mice per genotype. (F) ELISA measurements of relative af-
finity of NP-specific serum antibodies in Zbtb20+/+ and Zbtb20trap/trap fetal liver chimeras. Data were obtained by quantifying the ratio of high-affinity 
(NP4 binding) to total (NP16 binding) NP-specific antibodies at 11 wk after alum-adjuvanted NP-CGG immunization. Mean values ± SEM are shown 
along with individual data points. Data are representative of three experiments, each with two to eight mice per genotype. Statistical significance was 
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experiments confirm that BM plasma cells are formed in nor­
mal numbers in ZBTB20­deficient chimeras irrespective of 
the adjuvant used. Instead, these data suggest that intrinsic pro­
liferative or survival differences between alum­ and TLR ligand–
induced BM plasma cells underlie the selective dependence 
on ZBTB20.
ZBTB20 regulates survival of plasma cells
After their migration to the BM, plasma cell precursors prolif­
erate for several weeks and then can survive for years (Benner 
et al., 1981; Han et al., 1995; Manz et al., 1997; Smith et al., 1997; 
Slifka et al., 1998). The phenotypes of ZBTB20­deficient plasma 
cells are consistent with defects in either proliferation or sur­
vival. To specifically quantify plasma cell proliferation, ZBTB20­
deficient and wild­type chimeras were treated with blocking 
­CD40L at 3 wk after alum­ or TLR ligand–adjuvanted im­
munization to minimize new plasma cell formation. These ani­
mals were then fed BrdU in the drinking water for 4 d, and the 
level of incorporation was measured in NP­specific BM plasma 
cells. Irrespective of whether alum (Fig. 7 A) or TLR ligand 
(Fig. 7 B) adjuvants were used, ZBTB20­deficient and control 
adjuvants can induce remarkably persistent germinal center 
reactions, whereas alum adjuvants cannot (Dogan et al., 2009; 
Kasturi et al., 2011). These persistent germinal center reactions 
could potentially overcome ZBTB20 deficiency by continu­
ously generating and replenishing BM plasma cells. Thus, to 
further distinguish defects in plasma cell formation from main­
tenance, we administered a blocking antibody against CD40L 
at 2 wk after immunization of ZBTB20­deficient and control 
chimeras. Injection of this antibody led to the dissolution of 
germinal center reactions and prevented the formation of new 
dependent plasma cells (Fig. 6, A and B; Han et al., 1995). Thus, 
NP­specific antibodies and plasma cells in these ­CD40L–
treated animals were largely limited to those already formed at 
2 wk after immunization. After alum­adjuvanted immuniza­
tion, serum antibody deficiencies at 7 wk after immunization 
were still observed in ZBTB20­deficient chimeras relative to 
controls that were treated with the CD40L­blocking antibody 
(Fig. 6 C). In contrast, irrespective of whether mice were treated 
with the blocking antibody, antigen­specific titers between 
ZBTB20­deficient and control chimeras remained similar 
after TLR ligand­adjuvanted immunization (Fig. 6 D). These 
Zbtb20trap/trap BM plasma cells isolated at 2 wk after NP-CGG immunization adjuvanted with TLR ligands. Statistical significance was determined with 
a Mann–Whitney test. Each data point represents sequence from an individual cell. Error bars depict mean values ± SD. Data are cumulative from two 
independent experiments, each with two mice per genotype. (H and I) Flow cytometric analysis of splenic plasma cells at 2 wk after alum (H)- or TLR 
ligand–adjuvanted (I) immunization with NP-CGG. Mean values ± SEM are shown. Statistical significance was determined with an unpaired Student’s 
two-tailed t test. Data are cumulative from two experiments with eight to nine mice per genotype for each adjuvant.
 
Figure 6. ZBTB20 deficiency causes plasma cell– 
intrinsic defects. (A) Flow cytometric quantification of 
germinal center B cells after administration of blocking  
-CD40L antibody. Wild-type mice were immunized with 
alum-adjuvanted NP-CGG and then left untreated or in-
jected with 200 µg -CD40L at days 13, 14, and 15. Fre-
quencies of splenic lineage (CD4/8/Gr-1/Ter119) germinal 
center B cells were analyzed as shown at day 16 after im-
munization. Data are representative of two experiments 
with two mice per treatment group. (B) ELISPOT analysis of 
splenic plasma cells at 4 wk after immunization with TLR 
ligand–adjuvanted NP-CGG. Mice were left untreated or 
administered -CD40L at days 13, 14, and 15 as in A. Sta-
tistical significance was determined with an unpaired Stu-
dent’s two-tailed t test. Error bars depict mean values ± SD. 
Each data point represents one mouse. Data are represen-
tative of two experiments, each with three to four mice per 
group. (C and D) ELISA measurements of serum antibody 
titers (error bars depict geometric means ± 95% confidence 
interval) from Zbtb20+/+ and Zbtb20trap/trap fetal liver chime-
ras immunized with alum (C)- or TLR ligand–adjuvanted  
(D) NP-CGG and then treated with -CD40L or left untreated 
as in A. NP-specific serum antibody titers were quantified 
at 7 wk after immunization. Data are cumulative from two 
experiments with 8–12 (C) or 6–10 (D) mice per genotype. 
Statistical significance was determined with a Mann–Whitney 
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Figure 7. ZBTB20 regulates survival programs in plasma cells. (A and B) Flow cytometric analysis of BrdU incorporation in NP-specific BM plasma 
cells. Zbtb20+/+ and Zbtb20trap/trap animals were immunized with alum (A)- or TLR ligand–adjuvanted (B) NP-CGG. Immunized mice were then treated 
with three daily doses of blocking -CD40L antibody at 3 wk after immunization and then fed BrdU in the drinking water for 4 d. Gating strategies and 
data from an immunized control mouse not fed BrdU (top) and an immunized BrdU-fed control mouse (bottom) are shown to the left in A. Data are 
from either three to four (A) or three to six (B) mice per genotype. Data are cumulative from two independent experiments. Mean values ± SEM are 
shown. Statistical significance was determined with an unpaired Student’s two-tailed t test. ns, not significant. (C) ELISA measurements of serum NP-
specific IgG1 titers from Zbtb20+/+, Zbtb20trap/trap, Zbtb20+/+E-Bcl2, or Zbtb20trap/trapE-Bcl2 fetal liver chimeras at 6 wk after alum-adjuvanted NP-CGG 
immunization (error bars depict geometric means ± 95% confidence interval). Data are cumulative from three independent experiments with 6–10 
samples per genotype. Statistical significance was determined with the Mann–Whitney test. ***, P < 0.001. (D and E) Single-cell analysis of MCL1 ex-
pression. NP-specific Zbtb20+/+ and Zbtb20trap/trap BM cells were isolated 2 wk after alum-adjuvanted (D; Zbtb20+/+: n = 20; Zbtb20trap/trap: n = 15) or TLR 
ligand–adjuvanted (E; Zbtb20+/+: n = 13; Zbtb20trap/trap: n = 10) immunization, and transcript levels were assessed. (F) Single-cell analysis of CD37 ex-
pression. ZBTB20-deficient, NP-specific BM plasma cells were isolated 2 wk after immunization with alum (n = 15)- or TLR ligand–adjuvanted (n = 10) 
NP-CGG, and transcript levels were assessed and normalized to expression of the housekeeping gene Rpl13a. For D–F, mean values ± SEM are shown 
along with individual data points, each representing the expression level in a single cell. Data are cumulative from two independent experiments. Statis-
tical significance was determined with a Mann–Whitney test. *, 0.01 < P < 0.05. (G) Microarray analysis of Zbtb20+/+ and Zbtb20trap/trap polyclonal BM 
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replicates were arrayed for each genotype of BM plasma cells. Red represents high relative expression levels, and blue represents low relative expression 
levels. (H) qRT-PCR analysis of candidate ZBTB20-regulated transcripts. RNA from polyclonal CD45.2+ Zbtb20+/+ or Zbtb20trap/trap BM plasma cells was 
isolated for analysis. Transcript levels of each gene were measured in technical triplicates and were normalized to the mean Hprt expression of each 
sample. Three biologically distinct samples per genotype were measured. Mean values ± SEM are shown.
 
NP­specific BM plasma cells incorporated BrdU at similar rates, 
demonstrating no differences in proliferation. These data argue 
that survival deficits in plasma cells lead to the selective de­
pendence on ZBTB20 after alum­adjuvanted immunization.
To functionally test whether ZBTB20­deficient plasma 
cells are defective in their long­term survival, we first gener­
ated Zbtb20+/+ and Zbtb20trap/trap mice carrying an E-Bcl2 
transgene, and fetal liver chimeras were established. Mice car­
rying this particular transgene express BCL2 at high levels 
only in B cells, and previous studies have shown that BCL2 
expression can attenuate plasma cell apoptosis (Strasser et al., 
1991; Smith et al., 1994). These Zbtb20trap/trap BCL2­expressing 
fetal liver chimeras were then immunized with alum­adjuvanted 
NP­CGG. Unlike their Zbtb20trap/trap counterparts, NP­specific 
serum antibodies were maintained by Zbtb20trap/trap E-Bcl2 
chimeras at higher levels than in Zbtb20+/+ chimeras (Fig. 7 C). 
The ability of BCL2 expression to elevate serum antibody ti­
ters suggests defects in survival of ZBTB20­deficient plasma 
cells and further argues against defects in formation. Never­
theless, serum antibody titers in Zbtb20trap/trap E-Bcl2 chimeras 
were reduced relative to Zbtb20+/+ E-Bcl2 chimeras (Fig. 7 C). 
Similar trends were seen in BM plasma cells through ELISPOT 
analyses at 12 wk after immunization (not depicted). These 
data suggest that BCL2 expression leads to a partial rescue 
and/or that ZBTB20 regulates other parallel survival path­
ways in plasma cells. There are several candidate parallel cell 
death pathways that cannot be inhibited by BCL2 expression. 
For example, death receptor signals can bypass mitochondria 
and BCL2 to cause cell death (Scaffidi et al., 1998). In addi­
tion, BCL2 does not bind the proapoptotic mitochondrial 
protein NOXA; rather, NOXA uniquely binds antiapoptotic 
MCL1 and A1 (Chen et al., 2005; Kuwana et al., 2005; Willis 
et al., 2005; Certo et al., 2006; Kim et al., 2006). Of note, the 
balance of NOXA and MCL1 expression has been shown to 
be critically important for plasma and myeloma cell survival 
(Le Gouill et al., 2004; Qin et al., 2005; Wensveen et al., 2012; 
Peperzak et al., 2013).
The defects in Zbtb20trap/trap long­lived plasma cell accumu­
lation manifest over the course of several weeks. Thus, it is un­
likely that a dramatic deficiency in survival pathway expression, 
which would likely lead to rapid death, explains the observed 
phenotypes. We therefore used a single­cell quantitative RT­
PCR (qRT­PCR) assay to provide sufficient statistical power to 
identify candidate ZBTB20­dependent survival pathways other 
than BCL2 that may be only subtly dysregulated. Individual 
wild­type and ZBTB20­deficient NP­specific BM plasma cells 
were sorted at 2 wk after immunization, and transcript levels of 
several genes involved in apoptosis and in long­term antibody 
responses were evaluated. No differences were observed in the 
expression of several factors thought to be important in plasma 
cell survival, such as IL6ST, CD28, BAK, XBP1, PRDM1, IRF4, 
CD44, ITGA4, ITGB1, ITGB2, CXCR4, and TNFRSF13C 
(not depicted). However, expression of MCL1, which is critical 
for long­lived plasma cell survival (Peperzak et al., 2013), was 
statistically significantly reduced in NP­specific, ZBTB20­
deficient plasma cells after alum­adjuvanted immunization 
(Fig. 7 D). Transcription factors regulate programs of genes, and 
it is unlikely that any single downstream gene can fully explain 
the ZBTB20 phenotype; nevertheless, the reduction in MCL1 
expression may contribute to the defects in Zbtb20trap/trap plasma 
cells. Consistent with this interpretation, Peperzak et al. (2013) 
have shown that plasma cells express higher levels of MCL1 
than other B cells and are uniquely sensitive to perturbations in 
MCL1 levels.
One possible explanation for the adjuvant­specific require­
ment for ZBTB20 is that it regulates survival genes only when 
B cells are activated under certain conditions, e.g., in NP­specific 
plasma cells generated in response to alum­adjuvanted anti­
gen but not when using TLR ligand adjuvants. Arguing 
against this possibility, however, MCL1 expression was also 
reduced in ZBTB20­deficient plasma cells formed by TLR 
ligand–adjuvanted immunization (Fig. 7 E). A second possi­
ble explanation is that ZBTB20 regulates the same targets in 
all plasma cells, but that TLR ligands engage compensatory 
survival pathways. As an example of such a pathway, TLR 
ligands preferentially induce CD37 in ZBTB20­deficient 
plasma cells over those formed by alum­adjuvanted immu­
nization (Fig. 7 F). A recent study has shown the importance 
of this gene in maintaining long­lived plasma cells (van Spriel 
et al., 2012).
Because of the extreme paucity of antigen­specific BM 
plasma cells (typically <100 cells can be isolated per Zbtb20trap/trap 
chimera), it is technically challenging to perform unbiased 
microarray experiments to identify additional ZBTB20 tar­
gets. Thus, under the assumption that ZBTB20 regulates rele­
vant targets in all BM plasma cells, irrespective of their mode 
of formation, we performed microarray analyses on poly­
clonal Zbtb20+/+ and Zbtb20trap/trap populations. Several genes 
were clearly dysregulated by ZBTB20 deficiency (Fig. 7, 
G and H). Although the collective dysregulation of multiple 
genes likely underlies the ZBTB20­deficient phenotype, we 
noted in particular that RGS1 expression was elevated in 
ZBTB20­deficient plasma cells. Previous studies have shown 
that the proper expression of RGS1 is essential for plasma cell 
localization and responsiveness to prosurvival chemokines 
(Bowman et al., 1998; Moratz et al., 2000, 2004; Shi et al., 
2002). These data suggest that ZBTB20 regulates survival 
pathways in all long­lived plasma cells but that specific modes 
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critical for long­term plasma cell survival in the T­independent 
response. Our data raise the intriguing possibility that distinct 
transcription factors are used by B cells to regulate durable an­
tibody immunity in response to different types of infections.
In this regard, other transcription factors have been linked 
to the generation of durable antibody responses, yet ZBTB20 
is the first reported to specifically control plasma cell lifespan. 
Unlike ZBTB20, the transcription factor AIOLOS is required 
for the formation of long­lived plasma cells, and this require­
ment is likely secondary to its role in upstream germinal center 
reactions (Cortés and Georgopoulos, 2004). Other transcrip­
tion factors, such as BLIMP1, IRF4, and XBP1, are required for 
differentiation and secretory programs in all ASCs, including 
short­lived plasma cells (Reimold et al., 2001; Shapiro­Shelef 
et al., 2003, 2005; Klein et al., 2006; Sciammas et al., 2006). 
Thus, through functional analyses of genes upstream and down­
stream of ZBTB20, novel pathways that specifically regulate 
the lifespan of plasma cells and the duration of immunity may 
be revealed in future studies.
Although vaccine development and optimization have 
historically been performed empirically, modern approaches 
have the potential to provide molecular guides to rationally 
improve vaccines. Recent studies on both human influenza 
and yellow fever vaccines have demonstrated the feasibility 
and clinical value in such molecular approaches (Querec et al., 
2009; Nakaya et al., 2011). The induction of lifelong protec­
tion is a particularly important metric for a vaccine’s success, 
yet little is known about the immunogenic or molecular de­
terminants that drive an ultra­durable antibody response. The 
discovery of ZBTB20 as an adjuvant­specific transcriptional 
regulator of plasma cell survival provides a genetic foothold to 
identify pathways that differentially regulate durable versus 
transient vaccine responses. Importantly, our findings also jus­
tify further research on the use of pathogen­derived adjuvants 
to elicit maximally durable antibody responses.
MATERIALS AND METHODS
Mice. All animal procedures were approved by the Animal Studies Com­
mittee at Washington University in St. Louis. C57BL/6N and B6.SJL mice 
were purchased from the National Cancer Institute, and B6.Cg­IghA  
Thy1AGpi1A mice were purchased from the Jackson Laboratory. Zbtb20+/trap 
mice were generated using a gene­trapped C57BL6/N mouse embryonic 
stem cell line (IST12271A5; Texas A&M Institute for Genomic Medicine) 
by the Transgenic Knockout Microinjection Core facility at Washington 
University in St. Louis. Mice were first crossed to C57BL6/N (National 
Cancer Institute) for one generation and then maintained through heterozy­
gous intercrosses. In Fig. 1 A, wild­type controls were B6.SJL mice. For all 
other experiments, littermate controls were used for fetal liver reconstitu­
tions. Genotyping of Zbtb20 alleles was performed using primers specific for 
the wild­type allele, 5­CTCAGCCTCTGTGGCACATCACAGCCA­
CTT­3 (forward) and 5­GTTCCTTATCTGCCCTACCTTATCT­
CATG­3 (reverse); and a reverse primer specific for the gene­tapped allele, 
5­CTTGCAAAATGGCGTTACTTAAGC­3.
Fetal liver reconstitutions. Fetal livers were collected from Zbtb20+/+ or 
Zbtb20trap/trap embryos between 14.5 and 17.5 d postcoitus, homogenized 
into single­cell suspensions, and transplanted by retroorbital injection into 
8–12­wk­old 800 cGy–irradiated B6.SJL­Ptprca Pepcb or B6.Cg­IghA Thy1AGpi1A 
mice. Mice were immunized 8–16 wk after reconstitution.
DISCUSSION
Durable antibody production is a critical feature of successful 
vaccines. As such, a deeper understanding of the molecular basis 
of plasma cell survival could guide the rational improvement of 
vaccines, yet relatively little is known on this subject. Here we 
have shown that long­term survival of plasma cells after immu­
nization with antigen and alum, the most prevalent adjuvant 
used in vaccines (Marrack et al., 2009), is ZBTB20 dependent. 
In contrast, long­lived plasma cells produced in response to 
TLR­based adjuvants are ZBTB20 independent. To our knowl­
edge, this is the first direct evidence that plasma cells engage 
distinct survival programs, which, in turn, are highly dependent 
on the adjuvant used during immunization.
Most adjuvants are thought to act only indirectly on B cells, 
and not at all on plasma cells once they have been generated 
(Richard et al., 2008). Therefore, it was surprising for us to find 
that ZBTB20 is an alum­specific, B cell–intrinsic factor re­
quired for long­term antibody responses. Alum initially acti­
vates macrophages and monocytic inflammatory DC precursors 
(Jordan et al., 2004; Eisenbarth et al., 2008; Franchi and Núñez, 
2008; Kool et al., 2008a,b; Li et al., 2008; McKee et al., 2009). 
These APCs prime CD4+ T lymphocytes, which then migrate 
into B cell follicles and germinal centers to assist in antibody 
responses (Mannhalter et al., 1985; Ansel et al., 1999; Breitfeld 
et al., 2000; Schaerli et al., 2000; Crotty et al., 2003; Allen et al., 
2007; Yu et al., 2009; Victora et al., 2010). We suspect that 
ZBTB20 regulates the capacity of B cells to receive help from 
Tfh cells in germinal centers after priming by alum­activated 
myeloid cells, in some way augmenting the plasma cell survival 
program to generate a persistent antibody response. The impli­
cation of this proposed mechanism is that BM plasma cell lifes­
pan is imprinted during ontogeny within the germinal center 
reaction (Tarlinton, 2006; Amanna and Slifka, 2010).
It is unclear why the ability to mount durable antibody 
responses after challenge with aluminum salts would be under 
a strong selection pressure during evolution. However, alum 
adjuvants trigger responses that are in many ways similar to 
those elicited by clinically important helminth infections, such 
as schistosomiasis. Like alum, Schistosoma mansoni infections 
induce a heavily Th2­biased response and activate the NLRP3 
inflammasome but do not activate TLR signaling (Kane et al., 
2008; Ritter et al., 2010). Future studies will determine whether 
ZBTB20 is required for durable antibody responses to these 
types of infections. It also remains to be seen whether other 
transcription factors are required for durable antibody responses 
to infections that do activate TLRs, yet it is worth noting that 
expression of ZBTB32, another BTB­POZ family transcrip­
tion factor, is induced in plasma cells specifically upon LPS 
stimulation, but not after alum­adjuvanted immunization 
(Bhattacharya et al., 2007; Yoon et al., 2012). Several studies 
have demonstrated the ability of T­independent antigens to in­
duce long­lived plasma cell formation (Taillardet et al., 2009; 
Racine et al., 2011; Bortnick et al., 2012; Foote et al., 2012). 
Because our current study focused on the antibody response to­
ward T­dependent antigens, additional work will be necessary to 
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peroxidase (BD), and tetramethylbenzidine (Dako) was used to detect per­
oxidase reactivity, 2N H2SO4 was used to quench the reaction, and optical 
densities were quantified at 450 nm. The end­point titer of each sample was 
determined using Prism software (GraphPad Software) from a one­phase ex­
ponential decay curve defined as the dilution that generates an OD450 value 
of the background plus 3 SD.
ELISPOT assays. For the detection of antigen­specific ASCs, MultiScreen 
filter plates (EMD Millipore) were coated with 50 µg/ml NP16­BSA or with 
40 µg/ml of recombinant WNV E protein in PBS overnight. Splenocytes at 
2 wk after immunization were seeded at 4.0 × 105 cells/well; BM cells of all 
time points and splenocytes after 2 wk were seeded at 5–10 × 106 cells/well. 
Cells were cultured in 100 µl RPMI/5% FBS. Technical triplication was 
performed for every sample. Plates were incubated overnight at 37°C. Wells 
were stained with biotinylated anti­IgG1A, anti­IgG1B, or anti–mouse IgG 
(­chain specific; Sigma­Aldrich) and then with streptavidin­conjugated 
horseradish peroxidase (BD). Spots were developed using 3­amino­9­
ethyl­carbazole (Sigma­Aldrich), and the reaction was quenched by rinsing 
wells with water. Spots were counted using an ImmunoSpot S6 Analyzer 
(CTL Laboratories).
RNA extraction, cDNA synthesis, and qRT-PCR. RNA extraction 
was performed either with TRIzol (Life Technologies) or with RNeasy 
Mini kit (QIAGEN). First strand cDNA synthesis was performed with Su­
perScript III Reverse transcription kit using oligo (dT) primers or random 
hexamers (Life Technologies) according to the manufacturer’s instructions. 
qRT­PCR was performed using SYBR Green PCR master mix (Applied 
Biosystems) on a Prism 7000 Sequence Detection System (Applied Biosys­
tems). Primer sequences are as follows: Zbtb20, 5­CAGCCAAACAGAAC­
TACGTCA­3 (forward) and 5­GCGTCACCATGTGCTTGATA­3  
(reverse); -actin, 5­CCTGAACCCTAAGGCCAAC­3 (forward) and 
5­ACAGCCTGGATGGCTACG­3 (reverse); Rn18S, 5­AAGACGGA­
CCAGAGCGAAAG­3 (forward) and 5­GCCAGTCGGCATCGTT­
TATG­3 (reverse); Hprt, 5­TCTTTGCTGACCTGCTGGATT­3 (forward) 
and 5­TTATGTCCCCCGTTGACTGAT­3 (reverse); Dnase1l3, 5­TGG­
TTTGGTTCCATTCCCCC­3 (forward) and 5­CACTGGCTTCTCA­
CATCCGT­3 (reverse); Rgs1, 5­AATGCAGTGGTCTCAGTCTCT­3 
(forward) and 5­CCTCACAAGCCAACCAGAAT­3 (reverse); Il2ra, 
5­TGAAGTGTGGGAAAACGGGG­3 (forward) and 5­GCAGGAAG­
TCTCACTCTCGG­3 (reverse); and Grap, 5­TACAGCTTCCAGGCT­
ACCGA­3 (forward) and 5­CTTGGGAACAAAACCCTCCG­3 (reverse).
Immunofluorescence. Unfixed spleens were frozen in O.C.T. compound, 
and 10­µm­thick sections were cut with a Microm HM 550 cryostat (Thermo 
Fisher Scientific). Sections were fixed in acetone at 20°C for 5 min and 
stained with anti–GL7­PE and anti–IgD­FITC (BD). Fluorescent images were 
scanned with a NanoZoomer 2.0­HT equipped with a Fluorescence Imaging 
Module (Hamamatsu Photonics). Germinal center areas were quantified using 
NDP.view software (Hamamatsu Photonics). Distinct GL7+ germinal center 
and surrounding IgD+ follicle perimeters were manually defined, and areas 
were calculated. Three Zbtb20+/+ and Zbtb20trap/trap chimeras each were ana­
lyzed. Six sections of 10­mm2 area, spaced at least 120 µm apart from each 
other in the z­dimension, were analyzed for each animal. For presentation, 
contrast adjustment was applied equally to the representative images of both 
genotypes shown in Fig. 4 B using Photoshop CS3 (Adobe).
-CD40L treatment, BrdU labeling, and analysis. Three doses of 200 
µg ­CD40L antibody (MR1; Bio X Cell) were intravenously administered 
on the indicated days. BrdU (Sigma­Aldrich) was given to mice in drinking 
water at 2 mg/ml for 4 d after MR1 treatment. On day 26 after immuniza­
tion, CD138+ BM plasma cells were enriched, stained for surface expression of 
B220 and CD138, and then processed and stained for incorporated BrdU with 
the FITC BrdU Flow kit (BD) according to the manufacturer’s instructions. 
NP­APC used in intracellular staining was made by conjugating allophyco­
cyanin (Sigma­Aldrich) with 4­hydroxy­3­nitrophenylacetyl­O­succinimide 
Immunizations. Mice were immunized intraperitoneally with a single 
dose of 100 µg NP­CGG (hapten protein ratio: 15:22; Bioresearch Tech­
nologies) either in 5% precipitated aluminum potassium sulfate (Thermo 
Fisher Scientific) in phosphate buffered saline or in an equal volume (100 µl) 
of Sigma Adjuvant System (containing monophosphoryl lipid A and treha­
lose dicorynomycolate; Sigma­Aldrich). For WNV, mice were vaccinated 
intraperitoneally with two doses of 100 µl West Nile–Innovator vaccine 
(Pfizer Animal Health) on two consecutive days.
Antibodies. The following purified monoclonal antibodies were purified 
from hybridoma supernatants by Bio X Cell: 2C11 (anti­CD3), GK1.5 (anti­
CD4), 53­6.7 (anti­CD8), 1D3 (anti­CD19), 6B2 (anti­B220), 8C5 (anti–
Gr­1), M1/70 (anti–Mac­1), TER119 (anti­Ter119), A20.1.7 (anti­CD45.1), 
AL1­4A2 (anti­CD45.2), E13­161­7 (anti–Sca­1), and A7R34 (anti–IL­7 
receptor ). Purified antibodies were conjugated with biotin, Pacific Blue, 
Alexa Fluor 488, Alexa Fluor 647, or Alexa Fluor 680 (Life Technologies) ac­
cording to the manufacturer’s instructions. The following antibodies were 
purchased from eBioscience: A2F10 (anti­Flk2), B3B4 (anti­CD23) conju­
gated with PE, II/41 (anti­IgM) conjugated with PerCP–eFluor 710, PK136 
(anti­NK1.1) conjugated with PerCP­Cy5.5, 2B8 (anti­CD117), RA3­6B2 
(anti­B220), M1/70 (anti­CD11b), RB6­8C5 (anti­Gr­1) conjugated with 
PE­Cy7, 11­26 (anti­IgD) conjugated with FITC, eBio129c (anti­PDCA­1), 
AA4.1 (anti­CD93) conjugated with APC, N418 (anti­CD11c), RA3­6B2 
(anti­B220) conjugated with APC–eFluor 780, 11­26 (anti­IgD) conjugated 
with eFluor 450, and GL­7 (anti–GL­7) conjugated with biotin. The follow­
ing antibodies were purchased from BioLegend: 93 (anti­CD16/32) conju­
gated with PerCP/Cy5.5, 16­10A1 (anti­CD80) conjugated with PE­Cy5, 
145­2C11 (anti­CD3) conjugated with Alexa Fluor 488, 7E9 (anti­CD21/35) 
conjugated with Pacific Blue, and RMG1­1 (anti­IgG1) conjugated with 
APC. The following antibodies were purchased from BD: 281­2 (anti­
CD138), S7 (anti­CD43), 53­6.7 (anti­CD8a), AF6­78 (anti­IgMB) conju­
gated with PE, DS­1 (anti­IgMA) conjugated with FITC, 140706 (anti­CCR6) 
conjugated with Alexa Fluor 647, 6C3 (anti­BP1) and 281­2 (anti­CD138) 
conjugated with biotin, and unconjugated R26­46 (anti­Ig). Streptavidin 
conjugated with Qdot 605 and goat anti–rat IgG (H+L) conjugated with 
Alexa Fluor 633 were purchased from Life Technologies.
Cell isolation and analysis. Splenic plasma cells were isolated from spleens 
at 7 d after immunization, and germinal center B cells were isolated from 
spleens at 14 or 28 d after immunization; NP­specific splenic memory B cells 
were isolated from spleens at 12–16 wk after immunization; donor­derived 
polyclonal BM plasmas were isolated from BM of fetal liver chimeras 8 mo 
after reconstitution. For splenic IgG1+ plasma cell isolation, depletion of 
non­B cells was performed by labeling with monoclonal antibodies specific 
to CD3, CD4, CD8, Gr­1, and TER119 and plating onto Petri dishes coated 
with goat anti–rat IgG (SouthernBiotech). Plates were incubated at 4°C for 
30 min, and nonadherent cells were collected. For BM CD138+ plasma cell 
enrichment, cells were labeled with biotinylated CD138 and enriched with 
streptavidin microbeads on LS columns (Miltenyi Biotec). For splenic NP­
specific memory B cell enrichment, splenocytes were labeled with unconju­
gated anti­Ig and enriched with anti–rat IgG MicroBeads (Miltenyi Biotec) 
on LS columns. Ig­enriched B cells were then stained with NP40­PE 
(Biosearch Technologies). All B cell subsets were then purified according to 
the schemes shown in Fig. 1 on a FACSAria II (BD). ­Galactosidase activity 
was measured using FluoReporter lacZ Flow Cytometry kit (Life Technolo­
gies) according to the manufacturer’s instruction.
Serological analysis. ELISA plates were coated overnight with 5 µg/ml 
NP16­BSA or NP4­BSA (Biosearch Technologies) or with WNV E protein 
(gift of M. Diamond, Washington University in St. Louis, St. Louis, MO), 
and serial dilutions of sera were plated onto coated plates. Technical dupli­
cation was performed for every serum sample. Wells were stained with 
biotinylated anti­IgG1A (10.9), anti­IgG1B (B68­2), anti­IgG1 (nonallo­
type specific; A85­1), anti­IgG2c (5.7), or anti­IgG2b (R12­3), purchased 
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5­AAAGCCAGCAGCACATTTCT­3 (reverse); CD37, 5­TTGCCTC­
AGCCTCATCAAGTA­3 (forward) and 5­GCAGTGGCACGAAG­
GACAAA­3 (reverse); Rpl13a, 5­CCATTGTGGCCAAGCAGGTA­3 
(forward) and 5­TCGGGAGGGGTTGGTATTCA­3 (reverse); and NeoR, 
5­GCGTTGGCTACCCGTGATA­3 (forward) and 5­GGAGCGGC­
GATACCGTAAA­3 (reverse). Raw log2 expression values were extracted 
using Singular software (Fluidigm) and then normalized by dividing by the 
log2 RPL13A expression value from the corresponding well. Wells without 
detectable RPL13A expression were excluded from further analysis. The 
genotype of each cell was determined by the presence (Zbtb20trap/trap) or ab­
sence (wild type) of neomycin expression.
Statistics. Means, geometric means, SEM, 95% confidence interval, un­
paired Student’s two­tailed t tests, Mann–Whitney tests, and one­phase ex­
ponential decay curve­fitting for end­point dilution estimation were calculated 
with Prism software.
Online supplemental material. Fig. S1 shows the gating strategy for 
cells shown in Fig. 1. Fig. S2 shows the gating strategy demonstrating 
normal B cell and other immune cell development in Zbtb20trap/trap chi­
meras. Online supplemental material is available at http://www.jem.org/ 
cgi/content/full/jem.20131821/DC1.
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